Biopharmaceutical company recognized for innovation in the development of immune-modulatory therapeutic cancer vaccines –NEW YORK, March 18, ...

Find the latest IO Biotech news from Fast company. See related business and technology articles, photos, slideshows and videos.

Enrollment Completed Ahead of Schedule -- -- Initial Data Expected in 2025 -- NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company ...

Preparations for submission of a Biologics License Application (BLA) for Cylembio® (imsapepimut and etimupepimut, adjuvanted) to FDA by year end ...

The full IO Biotech team is proud to be leading the next frontier of immune-oncology with the development of therapeutic cancer vaccines for these and other difficult-to-treat cancers. Our ...